Evidence & concentration worksheet · Healing & Recovery
Ara-290 16 mg
Controlled trials exist, but there is no approved consumer product or prescribing label. Trial doses apply only inside their monitored study designs, not to online research vials.
Evidence review
Investigational trial context — not self-use instructions
Controlled trials exist, but there is no approved consumer product or prescribing label. Trial doses apply only inside their monitored study designs, not to online research vials.
How it works
ARA-290, later called cibinetide, is an 11-amino-acid peptide derived from a surface region of erythropoietin and designed to study tissue-protective signaling without stimulating red-blood-cell production. It is not epoetin, and it has no FDA-approved product or indication.
Benefits & side effects
A 22-person randomized pilot in sarcoidosis-associated small-fiber neuropathy evaluated four weeks of treatment and reported improvement in a symptom measure.[1] A 64-person phase 2b trial found an increase in corneal nerve-fiber area at one tested dose, a surrogate measure; the placebo-corrected pain result in the relevant subgroup was not statistically significant.[2]
These results are hypothesis-generating and do not establish cibinetide for neuropathic pain, nerve repair, metabolic control, eye disease, recovery, or general anti-inflammatory use.
Calculator
Concentration and measurement calculator
Use this only to check arithmetic from an authoritative product label, registered study protocol, or qualified clinician.
Arithmetic only — not a dose recommendation
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Enter only a concentration and target supplied by an authoritative product label, a registered study protocol, or a qualified clinician. A correct conversion does not establish that a substance, vial, route, or dose is safe or effective.
Source concentration
Source-supplied target
References
References
- Molecular Medicine — Randomized pilot study of ARA-290 in sarcoidosis small-fiber neuropathy (2012)
- Investigative Ophthalmology & Visual Science — Phase 2b trial of cibinetide in sarcoidosis-associated small nerve-fiber loss (2017)
- U.S. FDA — Orphan drug designation record for sarcoidosis neuropathic pain (2011)